Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma

International Journal of Oncology

Volumn 48, Issue 4, 2016, Pages 1599-1607

  Amatya, Vishwa Jeet ^a   Mawas, Amany Sayed ^a,b   Kushitani, Kei ^a   El Din, Mouchira M Mohi ^b   Takeshima, Yukio ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b South Valley University   (Egypt)

Author keywords

functional assay; mesothelioma; microRNA; miR 1; miR 214; PIM1

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 182; MICRORNA 183; MICRORNA 214; PROTEIN KINASE PIM 1; UNCLASSIFIED DRUG; MIRN1 MICRORNA, HUMAN; MIRN214 MICRORNA, HUMAN; PIM1 PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MESOTHELIOMA CELL LINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA PROBE; WESTERN BLOTTING; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84959017751     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3358     Document Type: Article

References (43)

1. Weill H, Hughes JM, and Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med. 61: 438-441, 2004.
2. Centers for Disease Control, and Prevention (CDC): Malignant mesothelioma mortality - United States, 1999-2005. MMWR Morb Mortal Wkly Rep. 58: 393-396, 2009.
3. Takeshima Y, Inai K, Amatya VJ, Gemba K, Aoe K, Fujimoto N, Kato K, and Kishimoto T. Accuracy of pathological diagnosis of mesothelioma cases in Japan: Clinicopathological analysis of 382 cases. Lung Cancer. 66: 191-197, 2009.
4. Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, and Inai K. CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. Oncol Rep. 29: 21-28, 2013.
5. Pass HI, Vogelzang N, Hahn S, and Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer. 28: 93-174, 2004.
6. Robinson BW, and Lake RA. Advances in malignant mesothelioma. N Engl J Med. 353: 1591-1603, 2005.
7. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, Gennaro V, Romanelli A, Chellini E, Pascucci C, et al. Survival of pleural malignant mesothelioma in Italy: A population-based study. Int J Cancer. 124: 201-207, 2009.
8. He L, and Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5: 522-531, 2004.
9. Drakaki A, and Iliopoulos D. MicroRNA gene networks in Oncogenesis. Curr Genomics. 10: 35-41, 2009.
10. Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, et al. Role of microRNAs in malignant mesothelioma. Cell Mol Life Sci. 71: 2865-2878, 2014.
11. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, and Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic, and prognostic implications. Am J Respir Cell Mol Biol. 42: 312-319, 2010.
12. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res. 17: 4965-4974, 2011.
13. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, et al. hsa-miR-29cis linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 70: 1916-1924, 2010.
14. Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA, Kelsey KT, and Marsit CJ. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 127: 2859-2869, 2010.
15. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, et al. Association of miR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 6: e18232, 2011.
16. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson BW, et al. Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 7: 1184-1191, 2012.
17. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, et al. Establishment, and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 97: 387-394, 2006.
18. Gebäck T, Schulz MM, Koumoutsakos P, and Detmar M. TScratch: A novel, and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 46: 265-274, 2009.
19. Lamprecht MR, Sabatini DM, and Carpenter AE. CellProfiler: Free, versatile software for automated biological image analysis. Biotechniques. 42: 71-75, 2007.
20. Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, and Inai K. Overexpression of CD26/DPPIV in mesothelioma tissue, and mesothelioma cell lines. Oncol Rep. 26: 1369-1375, 2011.
21. Milano MT, and Zhang H. Malignant pleural mesothelioma: A population-based study of survival. J Thorac Oncol. 5: 1841-1848, 2010.
22. Furukawa S, Kawasaki Y, Miyamoto M, Hiyoshi M, Kitayama J, and Akiyama T. The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration. PLoS One. 8: e80609, 2013.
23. Han C, Zhou Y, An Q, Li F, Li D, Zhang X, Yu Z, Zheng L, Duan Z, and Kan Q. MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation, and migration by targeting MET. Tumour Biol. 36: 6715-6723, 2015.
24. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, and Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells, and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 283: 33394-33405, 2008.
25. Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, Ittmann M, and Ozen M. miR-1, and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS One. 9: e98675, 2014.
26. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N, et al. The functional significance of miR-1, and miR-133a in renal cell carcinoma. Eur J Cancer. 48: 827-836, 2012.
27. Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma M, and Liu JF. The tumor-suppressive function of miR-1 by targeting LASP1, and TAGLN2 in esophageal squamous cell carcinoma. J Gastroenterol Hepatol: Sep 28, 2015 (Epub ahead of print
28. Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee H, Kratzke RA, and Hoang CD. miR-1 induces growth arrest, and apoptosis in malignant mesothelioma. Chest. 144: 1632-1643, 2013.
29. Xia H, Ooi LL, and Hui KM. miR-214 targets β-catenin pathway to suppress invasion, stem-like traits, and recurrence of human hepatocellular carcinoma. PLoS One. 7: e44206, 2012.
30. Li B, Han Q, Zhu Y, Yu Y, Wang J, and Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 279: 2393-2398, 2012.
31. Wang F, Liu M, Li X, and Tang H. miR-214 reduces cell survival, and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 587: 488-495, 2013.
32. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, et al. MicroRNA profiling in prostate cancer - The diagnostic potential of urinary miR-205, and miR-214. PLoS One. 8: e76994, 2013.
33. Long H, Wang Z, Chen J, Xiang T, Li Q, Diao X, and Zhu B. microRNA-214 promotes epithelial-mesenchymal transition, and metastasis in lung adenocarcinoma by targeting the suppressorof-fused protein (Sufu). Oncotarget. 6: 38705-38718, 2015.
34. Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H, Du L, and Wang C. MicroRNA-214 suppresses oncogenesis, and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One. 10: e0118086, 2015.
35. Phatak P, Byrnes KA, Mansour D, Liu L, Cao S, Li R, Rao JN, Turner DJ, Wang JY, and Donahue JM. Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly, and indirectly through CUG-BP1. Oncogene: doi: 10.1038/onc.2015.271. [Epub ahead of print].
36. Tsukiji H, Takeshima Y, Amatya VJ, Kushitani K, and Inai K. Myogenic antigen expression is useful for differentiation between epithelioid mesothelioma, and non-neoplastic mesothelial cells. Histopathology. 56: 969-974, 2010.
37. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al. miRTarBase update 2014: An information resource for experimentally validated miRNA-Target interactions. Nucleic Acids Res 42D: D78-D85, 2014.
38. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 412: 822-826, 2001.
39. Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, Michalski CW, Friess H, and Kleeff J. Hypoxia-inducible protooncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 7: 1352-1359, 2008.
40. Warnecke-Eberz U, Bollschweiler E, Drebber U, Pohl A, Baldus SE, Hoelscher AH, and Metzger R. Frequent downregulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases. Oncol Rep. 20: 619-624, 2008.
41. Warnecke-Eberz U, Bollschweiler E, Drebber U, Metzger R, Baldus SE, Hölscher AH, and Mönig S. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 29: 4451-4455, 2009.
42. Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head, and neck, and is under the control of epidermal growth factor receptor. Neoplasia. 11: 629-636, 2009.
43. Mondello P, Cuzzocrea S, and Mian M. Pim kinases in hematological malignancies: Where are we now, and where are we going?. J Hematol Oncol. 7: 95, 2014.